Lilly Claims Proof Of Concept For Neutralizing Antibodies In COVID-19 Therapy

Analysts called the interim data from a Phase II study of LY-CoV555 mixed, but Lilly insists that it has demonstrated a therapeutic role for neutralizing antibodies in fighting the novel coronavirus.

Coronavirus 2019-nCoV Blood Sample. Corona virus outbreaking. Epidemic virus Respiratory Syndrome. China
Lilly is advancing a COVID-19 therapy derived from a patient's blood sample

What Eli Lilly and Company calls proof-of-concept data for LY-CoV555, its neutralizing antibody candidate for the novel coronavirus, is meeting pushback from analysts, but a top Lilly exec told Scrip that the particulars and limitations of the dataset are less important than the demonstration that an antibody therapy can provide benefit to COVID-19 patients.

The Indianapolis pharma reported on 16 September that an interim analysis of the Phase II BLAZE-1 study showed that one...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip